40 YEARS OF IGF1: Role of IGF1 and EFN–EPH signaling in skeletal metabolism. (July 2018)

• Record Type: Journal Article
• Authors: Lindsey, Richard C; Rundle, Charles H; Mohan, Subburaman
• Is Part Of: Journal of molecular endocrinology. Volume 61:Number 1(2018)
• Page Start: T87
• Page End: T102
• Publication Date: 2018-07
• Subjects: IGF1 -- EFN -- EPH -- bone; Molecular endocrinology -- Periodicals; Endocrinology -- Periodicals; 616.407
• DOI: 10.1530/JME-17-0284
• Languages: English
• ISSNs: 0952-5041

Abstract

Abstract : Insulin-like growth factor 1(IGF1) and ephrin ligand (EFN)–receptor (EPH) signaling are both crucial for bone cell function and skeletal development and maintenance. IGF1 signaling is the major mediator of growth hormone-induced bone growth, but a host of different signals and factors regulate IGF1 signaling at the systemic and local levels. Disruption of the Igf1 gene results in reduced peak bone mass in both experimental animal models and humans. Additionally, EFN–EPH signaling is a complex system which, particularly through cell–cell interactions, contributes to the development and differentiation of many bone cell types. Recent evidence has demonstrated several ways in which the IGF1 and EFN–EPH signaling pathways interact with and depend upon each other to regulate bone cell function. While much remains to be elucidated, the interaction between these two signaling pathways opens a vast array of new opportunities for investigation into the mechanisms of and potential therapies for skeletal conditions such as osteoporosis and fracture repair.